Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases
Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses o...
Gespeichert in:
| Veröffentlicht in: | Expert reviews in molecular medicine 2018, Vol.20, p.e1-e1, Article e1 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1 |
|---|---|
| container_issue | |
| container_start_page | e1 |
| container_title | Expert reviews in molecular medicine |
| container_volume | 20 |
| creator | Celec, Peter Vlková, Barbora Lauková, Lucia Bábíčková, Janka Boor, Peter |
| description | Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue —tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases. |
| doi_str_mv | 10.1017/erm.2017.12 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989597759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_erm_2017_12</cupid><sourcerecordid>1988391211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-7eacd19331bb92c19ae4a306c2ef0f77c146c05bfc4adea161c48d8feb8c85fc3</originalsourceid><addsrcrecordid>eNptkL1PwzAUxC0EolCY2JElFiSU4hcnTcxWlU-pAgaYI8d5adMmcbCTIf89jlpQhZjeDT_duztCLoBNgEF0i6aa-E5MwD8gJxBMfY8LERzu6RE5tXbNGHAWh8dk5AsecA7BCXmfY1l6uUGk96-zO9qukBpdIi1q2sh2pZtVbwtd6mVPZZ1RaamkaaEraTZoBmpTZDX2NCssSov2jBzlsrR4vrtj8vn48DF_9hZvTy_z2cJTPAxbL0KpMhAuRJoKX4GQGEjOpsrHnOVRpFx2xcI0V4HMUMIUVBBncY5prOIwV3xMrre-jdFfHdo2qQqrXBlZo-5sAiIWoYiiUDj06g-61p2pXbqBirkAH8BRN1tKGW2twTxpTOFq9gmwZBg6cUMnw9AJ-I6-3Hl2aYXZL_uzrAO8nZ2sUlNkS9z7-o_hNy-7h0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1988391211</pqid></control><display><type>article</type><title>Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases</title><source>AUTh Library subscriptions: Cambridge Journals Online</source><creator>Celec, Peter ; Vlková, Barbora ; Lauková, Lucia ; Bábíčková, Janka ; Boor, Peter</creator><creatorcontrib>Celec, Peter ; Vlková, Barbora ; Lauková, Lucia ; Bábíčková, Janka ; Boor, Peter</creatorcontrib><description>Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue —tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases.</description><identifier>ISSN: 1462-3994</identifier><identifier>EISSN: 1462-3994</identifier><identifier>DOI: 10.1017/erm.2017.12</identifier><identifier>PMID: 29343314</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Adipocytes ; Apoptosis ; Autoimmune diseases ; Biochemistry ; Bioindicators ; Biology ; Biomarkers ; Blood & organ donations ; Blood cells ; Blood circulation ; Body fluids ; Chemotherapy ; Data processing ; Deoxyribonucleic acid ; Diagnostic software ; Diseases ; DNA ; Fetuses ; Gangrene ; Graft rejection ; Hemodialysis ; Kidney cancer ; Kidneys ; Multivariate analysis ; Organs ; Pathogenesis ; Physiology ; Plasma ; Pregnancy ; Renal cell carcinoma ; Review ; Sepsis ; Studies ; Systemic lupus erythematosus ; Transplantation ; Tumors ; Urinary tract ; Urine ; Womens health</subject><ispartof>Expert reviews in molecular medicine, 2018, Vol.20, p.e1-e1, Article e1</ispartof><rights>Copyright © Cambridge University Press 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-7eacd19331bb92c19ae4a306c2ef0f77c146c05bfc4adea161c48d8feb8c85fc3</citedby><cites>FETCH-LOGICAL-c355t-7eacd19331bb92c19ae4a306c2ef0f77c146c05bfc4adea161c48d8feb8c85fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S1462399417000126/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,780,784,4024,27923,27924,27925,55628</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29343314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Celec, Peter</creatorcontrib><creatorcontrib>Vlková, Barbora</creatorcontrib><creatorcontrib>Lauková, Lucia</creatorcontrib><creatorcontrib>Bábíčková, Janka</creatorcontrib><creatorcontrib>Boor, Peter</creatorcontrib><title>Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases</title><title>Expert reviews in molecular medicine</title><addtitle>Expert Rev. Mol. Med</addtitle><description>Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue —tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases.</description><subject>Adipocytes</subject><subject>Apoptosis</subject><subject>Autoimmune diseases</subject><subject>Biochemistry</subject><subject>Bioindicators</subject><subject>Biology</subject><subject>Biomarkers</subject><subject>Blood & organ donations</subject><subject>Blood cells</subject><subject>Blood circulation</subject><subject>Body fluids</subject><subject>Chemotherapy</subject><subject>Data processing</subject><subject>Deoxyribonucleic acid</subject><subject>Diagnostic software</subject><subject>Diseases</subject><subject>DNA</subject><subject>Fetuses</subject><subject>Gangrene</subject><subject>Graft rejection</subject><subject>Hemodialysis</subject><subject>Kidney cancer</subject><subject>Kidneys</subject><subject>Multivariate analysis</subject><subject>Organs</subject><subject>Pathogenesis</subject><subject>Physiology</subject><subject>Plasma</subject><subject>Pregnancy</subject><subject>Renal cell carcinoma</subject><subject>Review</subject><subject>Sepsis</subject><subject>Studies</subject><subject>Systemic lupus erythematosus</subject><subject>Transplantation</subject><subject>Tumors</subject><subject>Urinary tract</subject><subject>Urine</subject><subject>Womens health</subject><issn>1462-3994</issn><issn>1462-3994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkL1PwzAUxC0EolCY2JElFiSU4hcnTcxWlU-pAgaYI8d5adMmcbCTIf89jlpQhZjeDT_duztCLoBNgEF0i6aa-E5MwD8gJxBMfY8LERzu6RE5tXbNGHAWh8dk5AsecA7BCXmfY1l6uUGk96-zO9qukBpdIi1q2sh2pZtVbwtd6mVPZZ1RaamkaaEraTZoBmpTZDX2NCssSov2jBzlsrR4vrtj8vn48DF_9hZvTy_z2cJTPAxbL0KpMhAuRJoKX4GQGEjOpsrHnOVRpFx2xcI0V4HMUMIUVBBncY5prOIwV3xMrre-jdFfHdo2qQqrXBlZo-5sAiIWoYiiUDj06g-61p2pXbqBirkAH8BRN1tKGW2twTxpTOFq9gmwZBg6cUMnw9AJ-I6-3Hl2aYXZL_uzrAO8nZ2sUlNkS9z7-o_hNy-7h0g</recordid><startdate>2018</startdate><enddate>2018</enddate><creator>Celec, Peter</creator><creator>Vlková, Barbora</creator><creator>Lauková, Lucia</creator><creator>Bábíčková, Janka</creator><creator>Boor, Peter</creator><general>Cambridge University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2018</creationdate><title>Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases</title><author>Celec, Peter ; Vlková, Barbora ; Lauková, Lucia ; Bábíčková, Janka ; Boor, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-7eacd19331bb92c19ae4a306c2ef0f77c146c05bfc4adea161c48d8feb8c85fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adipocytes</topic><topic>Apoptosis</topic><topic>Autoimmune diseases</topic><topic>Biochemistry</topic><topic>Bioindicators</topic><topic>Biology</topic><topic>Biomarkers</topic><topic>Blood & organ donations</topic><topic>Blood cells</topic><topic>Blood circulation</topic><topic>Body fluids</topic><topic>Chemotherapy</topic><topic>Data processing</topic><topic>Deoxyribonucleic acid</topic><topic>Diagnostic software</topic><topic>Diseases</topic><topic>DNA</topic><topic>Fetuses</topic><topic>Gangrene</topic><topic>Graft rejection</topic><topic>Hemodialysis</topic><topic>Kidney cancer</topic><topic>Kidneys</topic><topic>Multivariate analysis</topic><topic>Organs</topic><topic>Pathogenesis</topic><topic>Physiology</topic><topic>Plasma</topic><topic>Pregnancy</topic><topic>Renal cell carcinoma</topic><topic>Review</topic><topic>Sepsis</topic><topic>Studies</topic><topic>Systemic lupus erythematosus</topic><topic>Transplantation</topic><topic>Tumors</topic><topic>Urinary tract</topic><topic>Urine</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Celec, Peter</creatorcontrib><creatorcontrib>Vlková, Barbora</creatorcontrib><creatorcontrib>Lauková, Lucia</creatorcontrib><creatorcontrib>Bábíčková, Janka</creatorcontrib><creatorcontrib>Boor, Peter</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Expert reviews in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Celec, Peter</au><au>Vlková, Barbora</au><au>Lauková, Lucia</au><au>Bábíčková, Janka</au><au>Boor, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases</atitle><jtitle>Expert reviews in molecular medicine</jtitle><addtitle>Expert Rev. Mol. Med</addtitle><date>2018</date><risdate>2018</risdate><volume>20</volume><spage>e1</spage><epage>e1</epage><pages>e1-e1</pages><artnum>e1</artnum><issn>1462-3994</issn><eissn>1462-3994</eissn><abstract>Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue —tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>29343314</pmid><doi>10.1017/erm.2017.12</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-3994 |
| ispartof | Expert reviews in molecular medicine, 2018, Vol.20, p.e1-e1, Article e1 |
| issn | 1462-3994 1462-3994 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989597759 |
| source | AUTh Library subscriptions: Cambridge Journals Online |
| subjects | Adipocytes Apoptosis Autoimmune diseases Biochemistry Bioindicators Biology Biomarkers Blood & organ donations Blood cells Blood circulation Body fluids Chemotherapy Data processing Deoxyribonucleic acid Diagnostic software Diseases DNA Fetuses Gangrene Graft rejection Hemodialysis Kidney cancer Kidneys Multivariate analysis Organs Pathogenesis Physiology Plasma Pregnancy Renal cell carcinoma Review Sepsis Studies Systemic lupus erythematosus Transplantation Tumors Urinary tract Urine Womens health |
| title | Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cell-free%20DNA:%20the%20role%20in%20pathophysiology%20and%20as%20a%20biomarker%20in%20kidney%20diseases&rft.jtitle=Expert%20reviews%20in%20molecular%20medicine&rft.au=Celec,%20Peter&rft.date=2018&rft.volume=20&rft.spage=e1&rft.epage=e1&rft.pages=e1-e1&rft.artnum=e1&rft.issn=1462-3994&rft.eissn=1462-3994&rft_id=info:doi/10.1017/erm.2017.12&rft_dat=%3Cproquest_cross%3E1988391211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1988391211&rft_id=info:pmid/29343314&rft_cupid=10_1017_erm_2017_12&rfr_iscdi=true |